Biodel Company Profile (NASDAQ:ALBO)

About Biodel (NASDAQ:ALBO)

Biodel logoBiodel Inc. is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia. It also develops insulin formulations for Type 1 and Type 2 diabetes patients. Its product pipeline includes RHI-based Ultra-Rapid-Acting Insulin, Analog-based Ultra-Rapid-Acting Insulin, Concentrated Ultra-Rapid-Acting Insulin and Glucagon. The Company's BIOD-531 is a Concentrated Ultra-Rapid-Acting Insulin and its insulin analog-based ultra-rapid-acting insulin product candidates include BIOD-123, BIOD-531, BIOD-238 and BIOD-250. It also conducts pre-clinical testing to develop liquid formulations of glucagon for hypoglycemic rescue and other indications.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ALBO
  • CUSIP: N/A
  • Web: www.albireopharma.com
Capitalization:
  • Market Cap: $148.49 million
  • Outstanding Shares: 6,292,000
Average Prices:
  • 50 Day Moving Avg: $24.50
  • 200 Day Moving Avg: $22.28
  • 52 Week Range: $11.40 - $37.69
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.78
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.24 million
  • Price / Sales: 13.21
  • Book Value: $4.96 per share
  • Price / Book: 4.76
Profitability:
  • EBIDTA: ($10,330,000.00)
Debt:
  • Current Ratio: 2.35%
  • Quick Ratio: 2.35%
Misc:
  • Average Volume: 32,975 shs.
  • Beta: 1.46
  • Short Ratio: 1.32
 

Frequently Asked Questions for Biodel (NASDAQ:ALBO)

What is Biodel's stock symbol?

Biodel trades on the NASDAQ under the ticker symbol "ALBO."

How were Biodel's earnings last quarter?

Biodel Inc. (NASDAQ:ALBO) released its quarterly earnings data on Monday, August, 21st. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.84) by $0.02. View Biodel's Earnings History.

Where is Biodel's stock going? Where will Biodel's stock price be in 2017?

5 brokerages have issued twelve-month price targets for Biodel's shares. Their forecasts range from $35.00 to $35.00. On average, they anticipate Biodel's stock price to reach $35.00 in the next year. View Analyst Ratings for Biodel.

Who are some of Biodel's key competitors?

How do I buy Biodel stock?

Shares of Biodel can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biodel's stock price today?

One share of Biodel stock can currently be purchased for approximately $23.60.


MarketBeat Community Rating for Biodel (NASDAQ ALBO)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  58 (Vote Outperform)
Underperform Votes:  82 (Vote Underperform)
Total Votes:  140
MarketBeat's community ratings are surveys of what our community members think about Biodel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biodel (NASDAQ:ALBO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $35.00 (48.31% upside)

Analysts' Ratings History for Biodel (NASDAQ:ALBO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Cowen and CompanyInitiated CoverageOutperformHighView Rating Details
7/18/2017Needham & Company LLCInitiated CoverageBuy -> Buy$35.00HighView Rating Details
6/30/2017WedbushInitiated CoverageOutperformHighView Rating Details
2/16/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuyN/AView Rating Details
1/25/2017William BlairInitiated CoverageOutperformN/AView Rating Details
(Data available from 8/23/2015 forward)

Earnings

Earnings History for Biodel (NASDAQ:ALBO)
Earnings by Quarter for Biodel (NASDAQ:ALBO)
Earnings History by Quarter for Biodel (NASDAQ ALBO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/21/20176/30/2017($0.84)($0.86)ViewN/AView Earnings Details
5/10/2017Q2 2017($1.11)($1.06)ViewN/AView Earnings Details
8/11/2016Q216($0.05)ViewN/AView Earnings Details
5/9/2016Q2($0.04)($0.09)ViewN/AView Earnings Details
2/16/2016Q1($0.08)($0.05)ViewN/AView Earnings Details
12/17/2015Q315($0.11)($0.05)ViewListenView Earnings Details
8/13/2015Q3($0.10)($0.12)ViewListenView Earnings Details
5/6/2015Q215($0.23)($0.27)ViewN/AView Earnings Details
2/12/2015Q115($0.18)($0.20)ViewN/AView Earnings Details
12/17/2014Q414($0.27)($0.16)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.26)($0.15)ViewN/AView Earnings Details
5/13/2014Q114($0.26)($0.29)ViewN/AView Earnings Details
2/6/2014Q4($0.19)($0.20)ViewN/AView Earnings Details
12/18/2013Q4($0.30)($0.04)ViewListenView Earnings Details
8/12/2013Q3 2013($0.37)($0.66)ViewN/AView Earnings Details
5/8/2013Q2 2013($0.43)($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biodel (NASDAQ:ALBO)
2017 EPS Consensus Estimate: ($3.43)
2018 EPS Consensus Estimate: ($4.03)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.91)($0.91)($0.91)
Q2 20171($0.87)($0.87)($0.87)
Q3 20171($0.79)($0.79)($0.79)
Q4 20171($0.86)($0.86)($0.86)
Q1 20181($1.01)($1.01)($1.01)
Q2 20181($1.01)($1.01)($1.01)
Q3 20181($1.01)($1.01)($1.01)
Q4 20181($1.00)($1.00)($1.00)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biodel (NASDAQ:ALBO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biodel (NASDAQ:ALBO)
Insider Ownership Percentage: 22.30%
Institutional Ownership Percentage: 12.33%
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)
Insider Trades by Quarter for Biodel (NASDAQ:ALBO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/20/2013Brian Jg PereiraDirectorSell4,734$2.26$10,698.84View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biodel (NASDAQ:ALBO)
Latest Headlines for Biodel (NASDAQ:ALBO)
Source:
DateHeadline
americanbankingnews.com logoQ3 2017 Earnings Forecast for Biodel Inc. (ALBO) Issued By William Blair
www.americanbankingnews.com - August 23 at 8:22 AM
americanbankingnews.com logoBiodel Inc. (ALBO) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - August 22 at 10:31 AM
finance.yahoo.com logoAlbireo Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 21 at 3:51 PM
americanbankingnews.com logoBiodel Inc. (ALBO) Coverage Initiated by Analysts at Cowen and Company
www.americanbankingnews.com - August 20 at 11:58 PM
americanbankingnews.com logoBiodel Inc. (ALBO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 16 at 10:54 AM
americanbankingnews.com logo Brokerages Anticipate Biodel Inc. (ALBO) Will Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - August 13 at 4:16 AM
finance.yahoo.com logoAlbireo to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 8 at 3:38 PM
americanbankingnews.com logoBiodel Inc. (ALBO) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - August 1 at 7:46 PM
nasdaq.com logoWhat's in the Cards for Humana (HUM) this Earnings Season?
www.nasdaq.com - July 31 at 3:50 PM
nasdaq.com logoWhat's in the Cards for Merrimack (MACK) in Q2 Earnings?
www.nasdaq.com - July 28 at 4:19 PM
americanbankingnews.com logoEndo International PLC (ENDP) and Biodel (NASDAQ:ALBO) Financial Review
www.americanbankingnews.com - July 16 at 2:11 PM
americanbankingnews.com logoBiodel Inc. (ALBO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 9:38 PM
americanbankingnews.com logoComparing Biodel (NASDAQ:ALBO) & Endo International PLC (ENDP)
www.americanbankingnews.com - July 7 at 8:28 PM
americanbankingnews.com logoZacks: Biodel Inc. (ALBO) Given $49.00 Average Price Target by Brokerages
www.americanbankingnews.com - July 6 at 10:37 PM
americanbankingnews.com logoBiodel (ALBO) & Endo International PLC (ENDP) Financial Comparison
www.americanbankingnews.com - July 6 at 12:32 AM
americanbankingnews.com logoResearch Analysts Set Expectations for Biodel Inc.'s FY2017 Earnings (NASDAQ:ALBO)
www.americanbankingnews.com - July 3 at 8:34 AM
americanbankingnews.com logoBiodel Inc. (NASDAQ:ALBO) Receives New Coverage from Analysts at Wedbush
www.americanbankingnews.com - July 1 at 12:02 PM
americanbankingnews.com logo Brokerages Anticipate Biodel Inc. (ALBO) Will Announce Earnings of -$0.87 Per Share
www.americanbankingnews.com - June 29 at 6:26 PM
americanbankingnews.com logoAnalyzing Biodel (ALBO) & Endo International PLC (ENDP)
www.americanbankingnews.com - June 27 at 12:40 AM
americanbankingnews.com logoAnalysts Anticipate Biodel Inc. (ALBO) to Post ($0.87) EPS
www.americanbankingnews.com - June 21 at 6:32 PM
americanbankingnews.com logo Analysts Expect Albireo Pharma, Inc. (ALBO) Will Post Earnings of -$0.87 Per Share
www.americanbankingnews.com - June 5 at 4:06 PM
americanbankingnews.com logoAlbireo Pharma, Inc. (ALBO) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - June 2 at 7:30 PM
nasdaq.com logoCompany Spotlight: Albireo Pharma - Nasdaq.com - Nasdaq
www.nasdaq.com - June 2 at 4:33 PM
americanbankingnews.com logoQ2 2017 EPS Estimates for Albireo Pharma, Inc. (ALBO) Raised by William Blair
www.americanbankingnews.com - June 2 at 7:18 AM
rttnews.com logoCompany Spotlight: Albireo Pharma
www.rttnews.com - June 2 at 1:46 AM
nasdaq.com logoALBO Spikes, GLYC Abuzz, FDA Approves 1st Generic Strattera For ADHD - Nasdaq
www.nasdaq.com - May 31 at 3:26 PM
globenewswire.com logoAlbireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
globenewswire.com - May 31 at 11:06 AM
americanbankingnews.com logoZacks: Albireo Pharma, Inc. (ALBO) Receives Consensus Rating of "Strong Buy" from Brokerages
www.americanbankingnews.com - May 31 at 8:34 AM
globenewswire.com logoAlbireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters' Option to Purchase ... - GlobeNewswire (press release)
globenewswire.com - May 30 at 8:36 PM
finance.yahoo.com logoAlbireo Announces Closing of $51.9 Million Public Offering Including Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - May 30 at 8:36 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Micron Technology, Atwood Oceanics, Xactly, Protagonist Therapeutics ... - Nasdaq
www.nasdaq.com - May 30 at 3:35 PM
streetinsider.com logoAlbireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share - StreetInsider.com
www.streetinsider.com - May 25 at 1:36 AM
streetinsider.com logoAlbireo Pharma (ALBO) Prices 2.2M Common Stock Offering at $20.50/Share
www.streetinsider.com - May 24 at 3:26 PM
finance.yahoo.com logoAlbireo Prices $45.1 Million Public Offering of Common Stock
finance.yahoo.com - May 24 at 3:26 PM
streetinsider.com logoAlbireo Pharma (ALBO) Commences Offering of Common Stock - StreetInsider.com
www.streetinsider.com - May 24 at 7:23 AM
finance.yahoo.com logoAlbireo Announces Proposed Public Offering of Common Stock
finance.yahoo.com - May 24 at 7:23 AM
americanbankingnews.com logoAlbireo Pharma, Inc. (ALBO) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 23 at 7:28 PM
finance.yahoo.com logoAlbireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
finance.yahoo.com - May 18 at 12:18 PM
streetinsider.com logoAlbireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for A4250 with Term into 2031
www.streetinsider.com - May 16 at 8:33 PM
americanbankingnews.com logoAlbireo Pharma, Inc. (ALBO) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - May 16 at 8:18 PM
streetinsider.com logoAlbireo Pharma (ALBO) Reports Two New U.S. Patents Allowed for ... - StreetInsider.com
www.streetinsider.com - May 16 at 3:31 PM
finance.yahoo.com logoAlbireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
finance.yahoo.com - May 16 at 3:31 PM
americanbankingnews.com logoAlbireo Pharma, Inc. (ALBO) Announces Earnings Results
www.americanbankingnews.com - May 11 at 5:10 PM
globenewswire.com logoAlbireo Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 1:39 AM
finance.yahoo.com logoAlbireo Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 10 at 8:38 PM
americanbankingnews.com logoAlbireo Pharma, Inc. (ALBO) Expected to Announce Earnings of -$0.91 Per Share
www.americanbankingnews.com - May 10 at 8:16 AM
americanbankingnews.com logo Brokerages Set $40.00 Target Price for Albireo Pharma, Inc. (ALBO)
www.americanbankingnews.com - May 5 at 10:42 AM
finance.yahoo.com logoAlbireo Announces Elobixibat Data from Japan to be Presented at DDW 2017
finance.yahoo.com - April 27 at 3:49 PM
streetinsider.com logoAlbireo Pharma (ALBO) to Present Pediatric Data for A4250 at The International Liver Congress - StreetInsider.com
www.streetinsider.com - April 24 at 3:28 PM
globenewswire.com logoPromising Pediatric Data for Albireo's A4250 to be Presented at The ... - GlobeNewswire (press release)
globenewswire.com - April 22 at 3:23 PM

Social

Chart

Biodel (ALBO) Chart for Wednesday, August, 23, 2017

This page was last updated on 8/23/2017 by MarketBeat.com Staff